Dichlorfluorescein | 81-87-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: Dichlorfluorescein
• 英文别名: 2-(4,5-Dichloro-6-hydroxy-3-oxo-3h-xanthen-9-yl)benzoic acid；2-(4,5-dichloro-3-hydroxy-6-oxoxanthen-9-yl)benzoic acid
• CAS: 81-87-8
• 化学式: C₂₀H₁₀Cl₂O₅
• 分子量: 401.202
• InChiKey: QZJUUWVEZFULLI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2',7'-dichlorofluorescin 在 xanthine oxidase potassium phosphate buffer 、 次黄嘌呤 作用下， 生成 Dichlorfluorescein
  参考文献：
  名称：

  细胞内探针2'，7'-二氯荧光素的氧化途径。

  摘要：

  2'，7'-二氯荧光素（DCFH）氧化为荧光产物目前用于评估细胞中的氧化应激。但是，对于可能导致DCFH氧化的酶促途径和非酶促途径，存在很大的不确定性。过氧化氢酶或羟基自由基清除剂二甲基亚砜可抑制铁/过氧化氢诱导的DCFH氧化；但是，超氧化物歧化酶（SOD）对DCFH氧化没有影响。羟基自由基的形成（由水杨酸氧化为2,3-二羟基苯甲酸表示）与DCFH氧化成正比，表明羟基自由基是铁/过氧化物介导的DCFH氧化的原因。利用由次黄嘌呤/黄嘌呤氧化酶组成的超氧化物生成系统，DCFH的氧化不受SOD，过氧化氢酶或去铁胺的影响，并通过从反应混合物中除去次黄嘌呤来刺激。相反，超氧化物歧化酶或次黄嘌呤的消除消除了超氧化物的形成。此外，过氧化钾不支持DCFH的氧化。因此，超氧化物不参与DCFH的氧化。煮沸的黄嘌呤氧化酶消除了其浓度依赖性的1 microM DCFH氧化，表明黄嘌呤氧化酶可以酶促地利用DCFH作

  DOI：

  10.1007/s002040050118

文献信息

• Improved Topical Medicaments and Methods for Photodynamic Treatment of Disease
  申请人：Provectus Pharmatech, Inc.

  公开号：EP2020242A2

  公开（公告）日：2009-02-04

  New photodynamic, topically-applicable medicaments and certain medical uses of such photodynamic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene. The halogenated xanthenes constitute a family of potent photosensitizers that become photoactivated upon illumination of the treatment site with visible wavelengths of light. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs; the mouth and digestive tract and related organs; the urinary and reproductive tracts and related organs; the respiratory tract and related organs; various other internal or external tissue surfaces, such as tissue surfaces exposed during surgery; and for treatment of a variety of conditions related to microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations including liquid, semisolid or aerosol delivery vehicles.

  本文描述了用于治疗人类或动物组织的新型光动力局部应用药物及其某些医疗用途，其中此类药物的主要活性成分是卤代呫吨。卤代呫吨构成了一个强效光敏剂家族，当治疗部位受到可见光波长的照射时，卤代呫吨会被光激活。在优选的实施方案中，此类药物用于治疗影响皮肤和相关器官、口腔和消化道及相关器官、泌尿道和生殖道及相关器官、呼吸道及相关器官、各种其他内部或外部组织表面，如手术中暴露的组织表面的各种病症，以及治疗与微生物或寄生虫感染有关的各种病症。在另一个优选的实施方案中，这类药物以各种配方生产，包括液体、半固体或气溶胶给药载体。
• Intracorporeal medicaments for photodynamic treatment of disease
  申请人：Photogen, Inc.

  公开号：US20010022970A1

  公开（公告）日：2001-09-20

  New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.

  本文描述了新的体腔内光动力药剂以及使用这种光动力药剂治疗人类或动物组织疾病的某些医疗用途和方法，其中这种药剂的主要活性成分是卤代呫吨或卤代呫吨衍生物。在优选的实施方案中，这类药物用于治疗影响皮肤和相关器官、口腔和消化道及相关器官、泌尿道和生殖道及相关器官、呼吸道及相关器官、循环系统及相关器官、头颈部、内分泌和淋巴系统及相关器官、各种其他组织，如结缔组织和手术中暴露的各种组织表面，以及表现出微生物或寄生虫感染的各种组织的各种疾病。在另一个优选的实施方案中，此类药物以各种剂型生产，包括液体、半固体、固体或气溶胶给药载体。
• Intracorporeal medicaments for high energy phototherapeutic treatment of disease
  申请人：Photogen, Inc.

  公开号：US20020001567A1

  公开（公告）日：2002-01-03

  New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The halogenated xanthenes constitute a family of potent radiosensitizers that become photoactivated upon irradiation of the treatment site with ionizing radiation. In embodiments of the present invention, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.

  本文描述了新的体腔内放射药剂以及使用这种高能光疗药剂治疗人体或动物组织的某些医疗用途和方法，其中这种药剂的主要活性成分是卤代呫吨或卤代呫吨衍生物。卤代呫吨构成了一个强效放射增敏剂家族，当电离辐射照射治疗部位时，这些增敏剂会发生光活化。在本发明的实施方案中，此类药剂可用于治疗影响皮肤和相关器官、口腔和消化道及相关器官、泌尿道和生殖道及相关器官、呼吸道及相关器官、循环系统及相关器官、皮肤及相关器官、口腔及消化道及相关器官、泌尿道及生殖道及相关器官、呼吸道及相关器官、循环系统及相关器官的各种疾病、循环系统及相关器官、头颈部、内分泌和淋巴系统及相关器官、各种其他组织，如结缔组织和手术中暴露的各种组织表面，以及出现微生物或寄生虫感染的各种组织。在另一个实施方案中，这类药剂以各种剂型生产，包括液体、半固体、固体或气溶胶给药载体。
• Medicaments for chemotherapeutic treatment of disease
  申请人：Photogen, Inc.

  公开号：US20020161035A1

  公开（公告）日：2002-10-31

  New chemotherapeutic medicaments and certain medical uses and methods for use of such chemotherapeutic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. Preferably, the halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal. The halogenated xanthenes constitute a family of useful chemotherapeutic agents that afford selective, persistent accumulation in certain tissues. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations useful for intracorporeal or topical administration, including in liquid, semisolid, solid or aerosol delivery vehicles.

  本文描述了新的化疗药物以及使用此类化疗药物治疗人类或动物组织疾病的某些医疗用途和方法，其中此类药物的主要活性成分是卤代呫吨或卤代呫吨衍生物。卤化氧杂蒽最好是玫瑰红或玫瑰红的功能衍生物。卤代呫吨构成了一个有用的化疗药物家族，可以在某些组织中选择性地、持久地蓄积。在优选的实施方案中，这类药剂用于治疗影响皮肤和相关器官、口腔和消化道及相关器官、泌尿道和生殖道及相关器官、呼吸道及相关器官、循环系统及相关器官、头颈部、内分泌和淋巴系统及相关器官、各种其他组织，如结缔组织和手术中暴露的各种组织表面，以及表现出微生物或寄生虫感染的各种组织的各种病症。在另一个优选的实施方案中，这类药剂以各种配方生产，可用于体腔内或局部给药，包括液体、半固体、固体或气溶胶给药载体。
• Ultrasound contrast using halogenated xanthenes
  申请人：Xantech Pharmaceuticals, Inc.

  公开号：US20030167006A1

  公开（公告）日：2003-09-04

  New contrast agents for ultrasound imaging and methods for use of such agents for imaging of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. Preferably, the halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal.

  本文描述了用于超声波成像的新型造影剂以及使用此类造影剂对人体或动物组织进行成像的方法，其中此类药物的主要活性成分是卤代呫吨或卤代呫吨衍生物。卤化呫吨最好是玫瑰红或玫瑰红的功能衍生物。